PODCAST: Hepatitis C overview

November 14, 2013

News

Article

Hepatitis C discussion with Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa.

Listen to Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa., discuss with Formulary the cost burden of hepatitis C to the healthcare system, what to expect in the hepatitis pipeline in the near future, and the most effective way to manage these drugs on the formulary.

Related Content

FDA Approves Imuldosa, the Fifth Stelara Biosimilar

Formulary Watch

October 14th 2024

Article

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

FDA Approves Hympavzi for Hemophilia A and B

Logan Lutton

October 11th 2024

Article

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

FDA Approves Itovebi for Metastatic Breast Cancer

Formulary Watch

October 11th 2024

Article

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination with Ibrance and fulvestrant. It will have a cost of $22,867 for a 28-day cycle.

Are PBMs Putting GLP-1 Drugs on Their Formularies?

Denise Myshko

October 11th 2024

Article

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.